Two years into dance, BEACON data clinched Pfizer-Array deal

A deal first floated in 2017 was finally consummated more than two years later after Array disclosed to Pfizer data from the Phase III BEACON CRC trial of its marketed cancer therapies Braftovi encorafenib and Mektovi binimetinib.